Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biofrontera (BFRI) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -89.84%.

  • Biofrontera's EBITDA Margin fell 3480.00% to -89.84% in Q3 2025 from the same period last year, while for Sep 2025 it was -47.40%, marking a year-over-year increase of 736.00%. This contributed to the annual value of -46.11% for FY2024, which is 2044.00% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's EBITDA Margin is -89.84%, which was down 59.73% from -56.25% recorded in Q2 2025.
  • Biofrontera's 5-year EBITDA Margin high stood at -13.63% for Q4 2024, and its period low was -371.60% during Q3 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -56.25% (2025), whereas its average is -63.78%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first slumped by 29,952bps in 2021, then spiked by 28,740bps in 2022.
  • Quarterly analysis of 5 years shows Biofrontera's EBITDA Margin stood at -20.51% in 2021, then plummeted by 3,451bps to -55.02% in 2022, then soared by 1,854bps to -36.48% in 2023, then spiked by 2,284bps to -13.63% in 2024, then plummeted by 3,480bps to -89.84% in 2025.
  • Its last three reported values are -89.84% in Q3 2025, -56.25% for Q2 2025, and -52.95% during Q1 2025.